NAUTILUS BIOTECHNOLOGY INC
NAUTNASDAQ🏆 #3345 by market capEarnings Oct 26US Equity
$0.89▲ $0.03 (+2.92%)
Market closed · at close1h—
24h▲ 2.9%
7d▼ 4.2%
14d▼ 13.9%
30d▼ 50.1%
1y▲ 24.6%
🏦Market Cap
$113M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
48
Weak
Trading Snapshot
- Day Range
- $0.88 – $0.90
- 52-Week Range
- $0.62 – $4.31
- Volume
- $4.32B
- Avg Volume
- $5.20B
- Shares Outstanding
- 127.3M
- Next Earnings
- Sep 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $11M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.45
- Dividend Yield
- —
Why Investors Own NAUT
- ✓High-growth profile — revenue up +10.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$11M▲ +8.7% YoY
Gross Margin (TTM)
41.4%▲ +2.3% YoY
Operating Income (TTM)
$3M▲ +8.7% YoY
Free Cash Flow (TTM)
$1M▲ +8.7% YoY
About NAUTILUS BIOTECHNOLOGY INC
A company profile for NAUTILUS BIOTECHNOLOGY INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
48/100
Analyst Price Target
ⓘAverage Target
$1.11
▲ +24.5% Upside
High Target$1.33
Low Target$0.90
Based on 28 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
NAUTILUS BIOTECHNOLOGY INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift NAUT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
NAUTILUS BIOTECHNOLOGY INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.